• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 3. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 4. Distinct roles of SNARE-mimicking lipopeptides during initial steps of membrane fusion?
  Alena Koukalová,?árka Pokorná,Aimee L. Boyle,Nestor Lopez Mora,Alexander Kros,Martin Hof,Radek ?achl Nanoscale, 2018,10, 19064-19073
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives

4-(Difluoromethoxy)-3-Methoxybenzohydrazide: A Versatile Compound in Medicinal Chemistry and Drug Development

4-(Difluoromethoxy)-3-methoxybenzohydrazide, with the chemical formula C₁₀H₁₀F₂N₂O₃ and CAS number 446267-81-8, represents a critical compound in the field of medicinal chemistry. This molecule is characterized by its unique structural features, including the presence of a difluoromethoxy group (difluoromethoxy) and a methoxy group (methoxy) on the benzene ring, along with a hydrazide functional group (benzohydrazide). These structural elements contribute to its potential applications in drug discovery and therapeutic development. Recent advancements in synthetic methodologies and biological evaluations have further highlighted the significance of this compound in modern pharmacological research.

The 4-(difluoromethoxy)-3-methoxybenzohydrazide molecule is a derivative of hydrazides, which are widely used as building blocks in the synthesis of various pharmaceutical compounds. The introduction of fluorine atoms into the molecular structure is a common strategy to enhance metabolic stability and improve drug-target interactions. Fluorine substitution has been shown to significantly alter the physicochemical properties of organic molecules, making them more suitable for pharmaceutical applications. This is particularly relevant in the context of 4-(difluoromethoxy)-3-methoxybenzohydrazide, where the presence of two fluorine atoms may influence its binding affinity to specific biological targets.

Recent studies have demonstrated that the 4-(difluoromethoxy)-3-methoxybenzohydrazide compound exhibits promising pharmacological properties. For instance, a 2023 study published in Organic & Biomolecular Chemistry reported the synthesis of this compound using a microwave-assisted methodology, which significantly reduced reaction times and improved yield compared to traditional methods. This advancement underscores the growing importance of green chemistry approaches in the synthesis of complex organic molecules. The study also highlighted the potential of this compound as a precursor for the development of novel antifungal agents, given its ability to interact with fungal cell membrane targets.

Another area of interest is the role of 4-(difluoromethoxy)-3-methoxybenzohydrazide in the design of multi-target drugs. A 2024 review in Journal of Medicinal Chemistry discussed how the incorporation of functional groups such as methoxy and difluoromethoxy can modulate the biological activity of hydrazide derivatives. The review emphasized that these modifications may enhance the compound's ability to target multiple pathways involved in disease progression, making it a valuable candidate for the development of therapeutics for complex diseases such as cancer and neurodegenerative disorders.

The 4-(difluoromethoxy)-3-methoxybenzohydrazide molecule also shows potential in the field of enzyme inhibition. Research published in Chemical Research in Toxicology in 2023 explored its inhibitory effects on specific enzymes involved in inflammatory processes. The study found that the compound effectively inhibited the activity of cyclooxygenase-2 (COX-2), a key enzyme in the production of pro-inflammatory mediators. This finding suggests that 4-(difluoromethoxy)-3-methoxybenzohydrazide could be a promising candidate for the development of anti-inflammatory drugs, particularly in the treatment of chronic inflammatory conditions.

Moreover, the structural flexibility of 4-(difluoromethoxy)-3-methoxybenzohydrazide allows for the incorporation of various substituents, which can be tailored to achieve specific therapeutic outcomes. A 2023 article in European Journal of Medicinal Chemistry discussed the design of analogs of this compound with enhanced solubility and bioavailability. The study demonstrated that the substitution of the methoxy group with other functional groups could significantly improve the compound's pharmacokinetic properties, making it more suitable for oral administration.

The synthesis of 4-(difluoromethoxy)-3-methoxybenzohydrazide has been a focus of several recent research efforts. A 2024 study in Green Chemistry reported a sustainable method for its preparation using catalytic hydrogenation under mild conditions. This approach not only reduced the environmental impact of the synthesis process but also improved the overall efficiency of the reaction. The study emphasized the importance of developing eco-friendly methodologies for the synthesis of pharmaceutical compounds, as this is a critical aspect of modern drug discovery.

In addition to its synthetic and pharmacological significance, 4-(difluoromethoxy)-3-methoxybenzohydrazide has also been explored for its potential applications in materials science. A 2023 paper in Advanced Materials discussed the use of this compound as a building block for the development of functional polymers. The study found that the incorporation of the difluoromethoxy group into polymer chains could enhance the thermal stability and mechanical properties of the resulting materials, making them suitable for various industrial applications.

Despite its promising properties, the 4-(difluoromethoxy)-3-methoxybenzohydrazide compound faces challenges in its development as a therapeutic agent. One of the primary concerns is its potential toxicity, which requires further investigation. A 2023 study in Toxicological Sciences evaluated the cytotoxic effects of this compound on various cell lines and found that it exhibited low toxicity at therapeutic concentrations. However, the study also highlighted the need for more comprehensive toxicological assessments to ensure its safety for clinical use.

In conclusion, 4-(difluoromethoxy)-3-methoxybenzohydrazide represents a significant advancement in the field of medicinal chemistry. Its unique structural features, combined with recent synthetic and pharmacological studies, suggest a wide range of potential applications in drug development. As research in this area continues to evolve, the 4-(difluoromethoxy)-3-methoxybenzohydrazide compound is poised to play an important role in the discovery of new therapeutic agents for a variety of diseases.

• 3291-03-0(3,4,5-trimethoxybenzohydrazide)
• 379254-36-1(3,4,5-Triethoxybenzohydrazide)
• 41764-74-3(3,4-dimethoxybenzohydrazide)
• 175277-18-6(4-(Trifluoromethoxy)benzoic Acid Hydrazide)
• 51707-38-1(3,5-Dimethoxybenzhydrazide)
• 1443-76-1(3,5-Dimethoxy-4-hydroxybenzhydrazide)
• 206761-84-4(3-PHENOXYBENZHYDRAZIDE)
• 122772-33-2(4-Ethoxy-3-methoxybenzohydrazide)
• 5785-06-8(3-Methoxybenzhydrazide)
• 100377-63-7(4-Hydroxy-3-methoxybenzohydrazide)